Equities research analysts at StockNews.com started coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Get Free Report) (TSE:AEZ) in a research note issued on Saturday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Aeterna Zentaris Trading Up 8.7 %
Shares of AEZS opened at $3.75 on Friday. The company’s fifty day simple moving average is $2.98 and its 200 day simple moving average is $3.05. Aeterna Zentaris has a 1-year low of $3.96 and a 1-year high of $12.00. The company has a market cap of $6.72 million, a price-to-earnings ratio of -0.25 and a beta of 1.55.
Aeterna Zentaris Company Profile
Read More
- Five stocks we like better than Aeterna Zentaris
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Meta Takes A Bow With Q1 Earnings – Watch For Tariff Impact in Q2
- High Flyers: 3 Natural Gas Stocks for March 2022
- Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be Cautious
- Stock Average Calculator
- Palantir Earnings: 1 Bullish Signal and 1 Area of Concern
Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.